Beam Therapeutics
BEAM
232 hedge funds and large institutions have $3.63B invested in Beam Therapeutics in 2021 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 74 increasing their positions, 70 reducing their positions, and 40 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 40
6% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 70
0% more funds holding
Funds holding: 231 → 232 (+1)
7% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $18.5M
1.24% less ownership
Funds ownership: 68.09% → 66.84% (-1.2%)
8% less capital invested
Capital invested by funds: $3.93B → $3.63B (-$304M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$97.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$46.9M |
| 3 |
BlackRock
New York
|
+$46.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$34.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$126M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$62.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$46.8M |
| 4 |
Two Sigma Investments
New York
|
-$16.4M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$12.5M |
BEAM Hedge Fund Activity: Q4 2021 in Review
232 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q4 2021, worth a combined $3.63B — down 7.7% from $3.93B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BEAM positions and 40 closed out — a net gain of 3 holders — while 74 added to existing stakes and 70 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $97.8M. The largest seller was HHLR Advisors, exiting entirely with an estimated $126M sold.
- 232 institutional investors held Beam Therapeutics (BEAM) as of Q4 2021, up from 231 in Q3 2021.
- Funds reported $3.63B of Beam Therapeutics stock for Q4 2021, down 7.7% quarter-over-quarter.
- 43 funds opened new Beam Therapeutics positions in Q4 2021 and 40 closed out, a net change of +3 holders.
- The largest Beam Therapeutics buyer in Q4 2021 was ARK Investment Management, an estimated $97.8M added.
- The largest Beam Therapeutics seller in Q4 2021 was HHLR Advisors, an estimated $126M sold.
Based on aggregated 13F filings for Q4 2021.